Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
NSF invests $104M in new engineering centers to advance biotechnology, robotics, and sustainability.
Jacksonville University's Davis College secures NSA/NSF grant, boosting cybersecurity education on the First Coast.
A study suggests that utilizing green hydrogen for Bitcoin mining could address its environmental impact. However, experts argue that Bitcoin ...
The Biden-Harris Administration is investing $5 billion in semiconductor research and development to strengthen domestic manufacturing and boost innovation. This ...
The National Science Foundation launches a pilot program to make AI research more accessible, democratizing resources for US-based researchers and ...
The article explores the role of artificial intelligence at the National Science Foundation, highlighting its investments, coordination efforts, and focus ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.